ClinicalTrials.gg
CompletedNCT05631938Updated Jul 11, 2025

Study to Evaluate the Effect of Renal Impairment and Dialysis Treatment on the Pharmacokinetics of a Single 3 mg Cytisinicline Dose

A Phase 1 interventional study of cytisinicline in Renal Impairment, sponsored by Achieve Life Sciences. Completed at 6 sites in 2 countries. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-11.

Sponsored by Achieve Life Sciences · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2023, 3 years 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Renal Insufficiency with a site in Portugal — 3 open to participants now, 4 under way, 1 of them phase 3. Renal Insufficiency · Portugal.

Enrollment
10th of 12
44 · median 555
Started
2023
the only one that year
Phase 1
3 of 14
1 open now
Registered
14th of 14
by date
Lead sponsor
1 of 14
Achieve Life Sciences

Among the 14 studies in Renal Insufficiency with a site in Portugal, this one is the 10th largest by enrollment of the 12 interventional ones that give a count, is the only one that started in 2023, is one of 3 in phase 1, and was the 14th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

3 of the 14 studies in Renal Insufficiency with a site in Portugal are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Portugal have not opened yet or have stopped. Only those recruiting at a site in Portugal →

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Renal Insufficiency with a site in Portugal, or all of them as a file.
02

Study summary

The primary objectives of this study are:

  1. To obtain information on the pharmacokinetics of cytisinicline following a single oral dose in subjects with varying degrees of renal impairment relative to matched controls with normal renal function.
  2. To investigate the extent of cytisinicline removal by hemodialysis.
03

Conditions studied

  • Renal Impairment

Browse trials for

Keywords

  • Dialysis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Free written prior to any procedure required by the study.
  • Ability to communicate well with the investigator, in a language understandable to the subject, and to understand and comply with the requirements of the study.
  • Willingness to accept and comply with all study procedures and restrictions.
  • Male or female subject between 18 and 75 years, inclusive, at Screening.
  • (BMI) of 18.0 to 35.0 kg/m\^2, inclusive, at Screening.
  • A female subject is eligible if she meets one of the following criteria:

    1. is of non- (underwent a permanent sterilization method [e.g., hysterectomy, bilateral salpingectomy and bilateral oophorectomy], is clinically diagnosed infertile, or is in a state); or
    2. is of childbearing potential and agrees to use an accepted method from at least 28 days prior to dose administration (prior to first dose administration for Group 5) until at least 1 month after the end of study (EOS).
  • Negative test results for anti- 1 and 2 antibodies (anti-HIV-1Ab and anti-HIV-2Ab), surface antigen (HBsAg) and anti- virus antibodies (anti-HCVAb).
  • Stable concomitant medications for at least 7 days prior to dose administration (first dose administration for Group 5) and up to the EOS.

Additional Inclusion Criteria for Subjects with Renal Impairment (Groups 2 to 5)

  • at Screening, determined by the equation, within:

    • 60-89 mL/min for Group 2 (mild renal impairment subjects).
    • 30-59 mL/min for Group 3 (moderate renal impairment subjects).
    • 15-29 mL/min for Group 4 (severe renal impairment subjects).
    • \<15 mL/min for Group 5 (ESRD subjects)
  • Subjects with ESRD are on dialysis for at least 3 months prior to Screening.
  • Systolic blood pressure (SBP) 100-180mmHg, diastolic blood pressure (DBP) 50-105 mmHg, and pulse rate 50-100 bpm (inclusive), at Screening and Admission.

Additional Inclusion Criteria for Subjects with Normal Renal Function (Group 1)

  • Estimated glomerular filtration rate (eGFR) ≥90 mL/min at Screening, determined by the Cockcroft-Gault equation.
  • No abnormalities on clinical laboratory tests at Screening.
  • Blood pressure and pulse rate at Screening within the following ranges:

    • SBP 90-140 mmHg, DBP 60-90 mmHg, and pulse rate 60-100 bpm (inclusive) for subjects \<65 years of age.
    • SBP 95-160mmHg, DBP 65-95 mmHg, and pulse rate 60-100 bpm (inclusive) for subjects ≥65 years of age.

Exclusion criteria

Exclusion Criteria:

  • Known /allergy reaction to cytisinicline substance or any of the .
  • History of renal, heart, and/or liver transplant.
  • History or clinical evidence of any disease and/or existence of any surgical or medical condition, which might interfere in a relevant manner with the absorption, distribution, metabolism, or excretion of the study treatment except for renal disease.
  • Symptoms of an acute infection in the 4-week period preceding Screening (e.g., bacterial, viral, or fungal infection).
  • History or clinical evidence of alcohol use disorder or substance use disorder according to 5 (DSM-5) classification, within the 3-year period prior to Screening.
  • Clinically relevant abnormalities on a 12-lead (ECG), recorded after 5 min in the supine position at Screening.
  • Currently using any creatine supplement.
  • Nicotine consumption (e.g., smoking, nicotine patch, nicotine chewing gum, or electronic cigarettes) from 48 hours prior to Admission.
  • Excessive caffeine consumption, defined as ≥800 mg per day at Screening.
  • Positive result in drugs-of-abuse or ethanol tests at Screening or Admission. NOTE: Subjects receiving stable treatment of methadone and benzodiazepines will be allowed to be enrolled in the study even if the urine drug screen test is positive.
  • Veins unsuitable for intravenous puncture on either arm (e.g., veins that are difficult to locate, access or puncture; veins with a tendency to rupture during or after puncture).
  • Participation in any clinical trial within the previous 2 months.
  • Loss of 250 mL or more blood within 3 months prior to screening.
  • If female, positive pregnancy test in serum at Screening or positive pregnancy test in urine at Admission.
  • If female, she is breast-feeding.

Additional Exclusion Criteria for subjects with Renal Impairment (Group 2 to 5)

  • Presence of severe cardiac disease.
  • History of severe renal artery stenosis.
  • Presence of unstable diabetes mellitus.
  • Acute, ongoing, recurrent, or chronic systemic disease other than renal function impairment that could interfere with the evaluation of the study results.
  • Presence of any organ disorder, except for renal function impairment, which might interfere with the PK of cytisinicline.
  • Use of any medication which might interfere with the PK of cytisinicline.
  • Clinically relevant findings in clinical laboratory tests (hematology, clinical chemistry, and urinalysis), except for those related to renal impairment, at Screening.

Additional Exclusion Criteria for Subjects with ESRD (Group 5)

  • Blood \<10 g/dL at Screening.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Experimental
    Group 1: Normal Renal Function

    Participants with normal renal function receive a 3 mg single dose of cytisinicline.

    Drug: cytisinicline

  • Experimental
    Group 2: Mild Renal Impairment

    Participants with mild renal impairment receive a 3 mg single dose of cytisinicline.

    Drug: cytisinicline

  • Experimental
    Group 3: Moderate Renal Impairment

    Participants with moderate renal impairment receive a 3 mg single dose of cytisinicline.

    Drug: cytisinicline

  • Experimental
    Group 4: Severe Renal Impairment

    Participants with severe renal impairment receive a 3 mg single dose of cytisinicline.

    Drug: cytisinicline

  • Experimental
    Group 5: ESRD Participants Undergoing Dialysis

    Participants with ESRD undergoing dialysis receive a 3 mg single dose of cytisinicline on 2 occasions: after and prior to a dialysis session.

    Drug: cytisinicline

Interventions

  • film-coated oral tablets containing 3 mg cytisinicline

    Also known as: cytisine

06

What researchers measure

Primary outcomes

  1. Plasma Pharmacokinetic (PK) Parameter: Maximum Observed Plasma Concentration (Cmax)

    Time frame: pre-dose; 00:20, 00:40, 01:00, 01:20, 01:40, 02:00, 02:30, 03:00, 04:30, 06:00, 08:00, 12:00; 24:00, 36:00 and 48:00 hours:minutes post-dose

  2. Plasma PK Parameter: Time of Occurrence of Cmax (Tmax)

    Time frame: pre-dose; 00:20, 00:40, 01:00, 01:20, 01:40, 02:00, 02:30, 03:00, 04:30, 06:00, 08:00, 12:00; 24:00, 36:00 and 48:00 hours:minutes post-dose

  3. Plasma PK Parameter: Area Under the Plasma Concentration Versus Time Curve (AUC) From Time of Dosing (t=0h) to the Time of the Last Measurable Concentration (AUC0-t)

    Time frame: pre-dose; 00:20, 00:40, 01:00, 01:20, 01:40, 02:00, 02:30, 03:00, 04:30, 06:00, 08:00, 12:00; 24:00, 36:00 and 48:00 hours:minutes post-dose

  4. Plasma PK Parameter: Total AUC Extrapolated to Infinity (AUC0-∞)

    Time frame: pre-dose; 00:20, 00:40, 01:00, 01:20, 01:40, 02:00, 02:30, 03:00, 04:30, 06:00, 08:00, 12:00; 24:00, 36:00 and 48:00 hours:minutes post-dose

  5. Plasma PK Parameter: Apparent Terminal Elimination Rate Constant (λz)

    Time frame: pre-dose; 00:20, 00:40, 01:00, 01:20, 01:40, 02:00, 02:30, 03:00, 04:30, 06:00, 08:00, 12:00; 24:00, 36:00 and 48:00 hours:minutes post-dose

  6. Plasma PK Parameter: Apparent Terminal Elimination Half-Life (t1/2)

    Time frame: pre-dose; 00:20, 00:40, 01:00, 01:20, 01:40, 02:00, 02:30, 03:00, 04:30, 06:00, 08:00, 12:00; 24:00, 36:00 and 48:00 hours:minutes post-dose

  7. Plasma PK Parameter: Fraction Unbound (fu)

    Time frame: pre-dose; 00:20, 00:40, 01:00, 01:20, 01:40, 02:00, 02:30, 03:00, 04:30, 06:00, 08:00, 12:00; 24:00, 36:00 and 48:00 hours:minutes post-dose

  8. Plasma PK Parameter: Apparent Clearance (CL/F)

    Time frame: pre-dose; 00:20, 00:40, 01:00, 01:20, 01:40, 02:00, 02:30, 03:00, 04:30, 06:00, 08:00, 12:00; 24:00, 36:00 and 48:00 hours:minutes post-dose

  9. Plasma PK Parameter: Apparent Volume of Distribution (V/F)

    Time frame: pre-dose; 00:20, 00:40, 01:00, 01:20, 01:40, 02:00, 02:30, 03:00, 04:30, 06:00, 08:00, 12:00; 24:00, 36:00 and 48:00 hours:minutes post-dose

  10. Urine PK Parameter: Amount of Drug Excreted in Urine (Ae)

    Time frame: pre-dose, 00:00-04:00 (groups 1-4), 00:00-06:00 (group 5), 04:00-08:00 (groups 1-4), 06:00-08:00 (group 5), 08:00-12:00, 12:00-24:00, 24:00-36:00 and 36:00-48:00 hours:minutes post-dose

  11. Urine PK Parameter: Fraction of Unchanged Drug Excreted in Urine (fe)

    Time frame: pre-dose, 00:00-04:00 (groups 1-4), 00:00-06:00 (group 5), 04:00-08:00 (groups 1-4), 06:00-08:00 (group 5), 08:00-12:00, 12:00-24:00, 24:00-36:00 and 36:00-48:00 hours:minutes post-dose

  12. Urine PK Parameter: Area Under the Urine Excretion Rate Curve From Time Zero to Last Measurable Observed Excretion Rate (AURC)

    Time frame: pre-dose, 00:00-04:00 (groups 1-4), 00:00-06:00 (group 5), 04:00-08:00 (groups 1-4), 06:00-08:00 (group 5), 08:00-12:00, 12:00-24:00, 24:00-36:00 and 36:00-48:00 hours:minutes post-dose

  13. Urine PK Parameter: Renal Clearance (CLR)

    Time frame: pre-dose, 00:00-04:00 (groups 1-4), 00:00-06:00 (group 5), 04:00-08:00 (groups 1-4), 06:00-08:00 (group 5), 08:00-12:00, 12:00-24:00, 24:00-36:00 and 36:00-48:00 hours:minutes post-dose

  14. Urine PK Parameter: Apparent Nonrenal Clearance (CLNR/F)

    Time frame: pre-dose, 00:00-04:00 (groups 1-4), 00:00-06:00 (group 5), 04:00-08:00 (groups 1-4), 06:00-08:00 (group 5), 08:00-12:00, 12:00-24:00, 24:00-36:00 and 36:00-48:00 hours:minutes post-dose

  15. PK Parameter in Dialysate, Group 5 (ESRD on-dialysis): Amount of Drug Recovered From Each Dialysate Collection (AD)

    Time frame: Day 1 pre-dialysis, post-dialysis (before the hemodialysis is stopped), and for 1 minute every hour during hemodialysis

  16. PK Parameter in Dialysate, Group 5 (ESRD on-dialysis): Cumulative Amount of Drug Recovered From the Dialysate (AD, total)

    Time frame: Day 1 pre-dialysis, post-dialysis (before the hemodialysis is stopped), and for 1 minute every hour during hemodialysis

  17. PK Parameter in Dialysate, Group 5 (ESRD on-dialysis): Partial Area Under the Curve Estimated From Predialyzer Samples Collected From Start of Dialysis (t0) to End of Dialysis (t1) (AUCt0-t1)

    Time frame: Day 1 pre-dialysis, post-dialysis (before the hemodialysis is stopped), and for 1 minute every hour during hemodialysis

  18. PK Parameter in Dialysate, Group 5 (ESRD on-dialysis): Dialysis Clearance (CLD)

    Time frame: Day 1 pre-dialysis, post-dialysis (before the hemodialysis is stopped), and for 1 minute every hour during hemodialysis

  19. PK Parameter in Dialysate, Group 5 (ESRD on-dialysis): Fraction of the Administered Dose That is Recovered in the Dialysate (Frem)

    Time frame: Day 1 pre-dialysis, post-dialysis (before the hemodialysis is stopped), and for 1 minute every hour during hemodialysis

Secondary outcomes

  1. Number of Participants With Clinically Significant Changes from Baseline in Body Weight

    Time frame: Baseline (pre-dose), 48 hours post-dose

  2. Number of Participants With Clinically Significant Changes from Baseline in Systolic and Diastolic Blood Pressure

    Time frame: Baseline (pre-dose), 2, 6, 24, 36 and 48 hours post-dose

  3. Number of Participants With Clinically Significant Changes from Baseline in Pulse Rate

    Time frame: Baseline (pre-dose), 2, 6, 24, 36 and 48 hours post-dose

  4. Number of Participants With Clinically Significant Changes from Baseline in Body Temperature

    Time frame: Baseline (pre-dose), 2, 6, 24, 36 and 48 hours post-dose

  5. Number of Participants With Clinically Significant Changes from Baseline in Hematology Values

    Hematology assessments include hemoglobin, red blood cell (RBC) count, hematocrit, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), red cell distribution width, white cell count with differential (neutrophil, eosinophil, basophil, lymphocyte and monocyte), platelet count and mean platelet volume.

    Time frame: Baseline (pre-dose), 48 hours post-dose

  6. Number of Participants With Clinically Significant Changes from Baseline in Biochemistry Values

    Biochemistry values include sodium, potassium, glucose, creatinine, estimated creatinine clearance, total, direct and indirect bilirubin, alkaline phosphatase (ALP), lactate dehydrogenase (LDH), aspartate aminotransferase (AST), alanine aminotransferase (ALT), gamma-glutamyltransferase (GGT), creatine phosphokinase (CPK), total protein and albumin.

    Time frame: Baseline (pre-dose), 48 hours post-dose

  7. Number of Participants With Clinically Significant Changes from Baseline in Coagulation Values

    Coagulation assessments include prothrombin rate, prothrombin time-international normalized ratio (INR) and activated partial thromboplastin time (aPTT).

    Time frame: Baseline (pre-dose), 48 hours post-dose

  8. Number of Participants With Clinically Significant Changes from Baseline in Urinalysis Values

    Urinalysis assessments include pH, specific gravity, protein, hemoglobin, glucose, ketones, bilirubin, nitrites, urobilinogen, and microscopy (if urine is available).

    Time frame: Baseline (pre-dose), 48 hours post-dose

  9. Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs)

    Time frame: Groups 1 to 4: approximately 25 days; Group 5: approximately 31 days

07

Study locations

6 sites
  • Hospital de Braga, Centro Clínico Académico Braga, Associação
    Braga, Braga District 4710-243, Portugal
  • BlueClinical Phase I
    Porto, Porto District 4250-449, Portugal
  • Early Phase Clinical Trials Unit | CHVNG/E + BlueClinical
    Vila Nova de Gaia, Porto District 4434-502, Portugal
  • Hospital Universitario de La Princessa
    Madrid, Madrid 28006, Spain
  • Hospital Clínico San Carlos
    Madrid, Madrid 28040, Spain
  • Hospital Universitario La Paz
    Madrid, Madrid 28046, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2023 to primary completion in Sep 2023, 7 months.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 7 months is below that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 18, 2022
First posted
Nov 30, 2022
StartActual
Jan 10, 2023
Primary completionActual
Sep 4, 2023
CompletionActual
Sep 4, 2023
Last update
Jul 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05631938
Responsible party
Sponsor
First posted
Nov 30, 2022
Start date
Jan 10, 2023
Primary completion
Sep 4, 2023
Completion
Sep 4, 2023
Last update
Jul 11, 2025

Study contacts

Serafim Guimarães, MD, PhD
principal investigator · Blueclinical, Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cytisine

Start the discussion